V
Vaxdyn
Spain · Biotech · Healthtech
Vaxdyn develops vaccines against antimicrobial-resistant bacteria, including its lead candidate K-VAX for Klebsiella pneumoniae and Acinetobacter baumannii.
Product and development
Vaxdyn’s proprietary vaccine platform is designed to address bacterial infections for which antibiotic resistance limits treatment options. Its lead candidate, K-VAX, targets Klebsiella pneumoniae and Acinetobacter baumannii and is ready to enter first-in-human evaluation.
The company is advancing its vaccine from preclinical development toward clinical testing. Its September Series A will fund the first-in-human Phase I trial of K-VAX, so the candidate remains investigational rather than an available vaccine.
- Product focus
- Vaccines against antimicrobial-resistant bacteria
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | €11M | Biovance Capital — LeadEuropean Innovation Council (EIC) Fund — ParticipantImpacto Andalucía Innovación y Desarrollo — Participant |